Comprehensive Explanation and Clinical Context: The PARIS Thrombosis Risk Score (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) is a clinical tool designed to predict the likelihood of stent thrombosis and major adverse cardiac events (MACE) among patients receiving dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Variables and Scoring: The score is derived from six parameters: Diabetes Mellitus (+1), Current Smoking (+1), Acute Coronary Syndrome (ACS) as PCI indication (+1), Prior PCI (+1), Stent Diameter < 3 mm (+1), and Multivessel PCI (+2). The total score ranges from 0 to 7 points. Risk Interpretation: A total score of 0–2 indicates Low Risk, 3–4 corresponds to Intermediate Risk, and >5 indicates High Risk for stent thrombosis or MACE within two years. Clinical Significance: The PARIS Thrombosis Risk Score provides clinicians with a validated framework to individualize DAPT duration and intensity, balancing ischemic protection with bleeding risks. It is particularly useful when used alongside bleeding risk models such as the PRECISE-DAPT score. Clinical Interpretation Summary: Higher PARIS scores indicate increased risk for thrombotic events following PCI. Patients with elevated scores may benefit from prolonged DAPT and closer clinical surveillance. References: 1. Baber U, et al. J Am Coll Cardiol. 2013;62(12):1068–1078.
2.
Baber U, et al. Circ Cardiovasc Interv. 2015;8(8):e002359.
3.
Yeh RW, et al. J Am Coll Cardiol. 2017;69(17):2224–2233.
4.
Valgimigli M, et al. Eur Heart J. 2023 – ESC Guidelines for ACS management.